JPRN-UMIN000002444
Recruiting
未知
Randomized study of anti-coagulant therapy to preventpostoperative deep venous thrombosis/pulmonary embolism - Randomized study of anti-coagulant therapy to preventpostoperative deep venous thrombosis/pulmonary embolism
unversity of tokushima, surgery0 sites300 target enrollmentOctober 1, 2009
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Patients after diegstive surgery classified high risk in DVT/PE prevention guide line
- Sponsor
- unversity of tokushima, surgery
- Enrollment
- 300
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate-I48 Atrial fibrillation and flutterAtrial fibrillation and flutterI48PER-087-06BOEHRINGER INGELHEIM PHARMA,
Active, not recruiting
Not Applicable
Randomized evaluation of long term anticoagulant therapy (RELY)comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non inferiority trial (RELY STUDY) - RELYprevention of stroke and systemic embolism in patients with non-valvular atrial fibrillationMedDRA version: 14.1Level: HLTClassification code 10000032Term: Cardiac conduction disordersSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2005-003894-26-ITBOEHRINGER ING.15,000
Active, not recruiting
Not Applicable
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial FibrillationEUCTR2005-003894-26-PTBoehringer Ingelheim Pharma GmbH & Co. KG15,000
Active, not recruiting
Phase 1
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYEUCTR2005-003894-26-GBBoehringer Ingelheim Ltd.18,000
Active, not recruiting
Not Applicable
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial FibrillationEUCTR2005-003894-26-DKBoehringer Ingelheim Pharma GmbH & Co KG18,000